Phase 3 Clinical Trials With Primary Completion Dates in April 2023

This is a list of Phase 3 trials with primary completion dates in April 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ACHVAchieve Life Sciences, Inc.2023-04-01Phase 3NCT05206370A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers
BTTXBetter Therapeutics, Inc.2023-04-01Phase 3NCT05094401Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
BVNRYBavarian Nordic A/S2023-04-01Phase 3NCT05329220ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
CASBFCanSino Biologics Inc.2023-04-01Phase 3NCT05517642IH Convidecia as Second Booster Dose Against Breakthrough Infections
EYPTEyePoint Pharmaceuticals, Inc.2023-04-01Phase 3NCT05070728Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)
IONSIonis Pharmaceuticals, Inc.2023-04-01Phase 3NCT04136184NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
KODKodiak Sciences Inc.2023-04-01Phase 3NCT04603937A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
KRONKronos Bio, Inc.2023-04-01Phase 3NCT05020665A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia
LIANLianBio2023-04-01Phase 3NCT05174416A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
MNKDMannKind Corporation2023-04-01Phase 3NCT04974528Afrezza® INHALE-1 Study in Pediatrics
RAREUltragenyx Pharmaceutical Inc.2023-04-01Phase 3NCT05139316A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)